PM360 2020 Trailblazer Awards Specialty Pharma/Biotech Company of the Year Greenwich Biosciences

Greenwich Biosciences is the U.S. leader in the field of prescription cannabinoid medicines to address serious medical conditions with limited treatment options. Along with parent company GW Pharmaceuticals, Greenwich has been advancing cannabinoid science for more than two decades, making great contributions to what is known about cannabinoids.

Greenwich Biosciences is the U.S. leader in cannabinoid prescription medicines. It is our passion and purpose to seek solutions that transform the lives of those living with rare neurological diseases.


  • Following initial approval of EPIDIOLEX in 2018 for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and difficult to treat conditions of childhood-onset epilepsy, the company secured FDA approval for EPIDIOLEX for patients with seizures associated with tuberous sclerosis complex (TSC, a rare genetic disorder) in 2020. EPIDIOLEX was the first-ever approval by the FDA for a cannabis plant-derived medicine.
  • The company is conducting a Phase 3 study of EPIDIOLEX in Rett syndrome, a rare, non-inherited, X-linked neurodevelopmental disorder with high unmet need.
  • Greenwich is planning a number of clinical studies on nabiximols (Sativex® outside of the U.S.) for treatment of multiple sclerosis spasticity, spinal cord injury spasticity, and in post-traumatic stress disorder with plans to submit nabiximols for FDA review as soon as data is available from one positive study. Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids THC and CBD as well as minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.

Social Responsibility

  • In response to the COVID-19 pandemic, Greenwich eliminated copays for commercially insured EPIDIOLEX patients in the U.S. through the end of 2020. Additionally, the company expanded its patient assistance program to help ensure that patients who lost their commercial insurance or do not have enough insurance due to the pandemic have access to EPIDIOLEX.
  • During public commentary opportunities with the FDA, Greenwich has advocated for incentives to encourage other companies to develop FDA-approved, cannabis-derived medicines so that more patients have the option of rigorously tested, clinically proven, and consistently manufactured products to treat serious illnesses.
  • To serve the communities employees live in, Greenwich has made donations to COVID research, food banks, and local institutions serving epilepsy patients as nominated by their colleagues.

Talent Development

  • The company held an inclusive leadership workshop for all people managers and enhanced its family friendly policies (e.g., parental and maternity leave) to continue to foster a culture that encourages inclusion and celebrates diversity.
  • Greenwich implemented a new global job architecture to provide employees with compensation opportunities that are competitive, equitable, and performance based.
  • The company launched its Leadership Excellence And Development (L.E.A.D.) training program, which covers a variety of focus areas including leading through change and uncertainty, leading in a virtual environment, giving and receiving feedback, and empowerment and delegation.


You May Also Like

PM360 2018 Innovative Startup OI Infusion Services

OI Infusion Services Woody Baum, CEO Today, the hospital outpatient center remains the ...

PM360 2020 Innovative Company Mission Bio

Mission Bio Hannah Viernes, Mission Bio Only 3% of cancer drugs tested in ...

PM360 2021 Trailblazer Awards Direct-to-Patient Campaign Gold Winner Takeda and Snow Companies

Takeda Hemophilia Starter Kit (Takeda, Snow Companies) Hemophilia is a bleeding disorder that requires ...